All PlansPrior AuthMedium impact
Pharmacy Medical Policy Updates
Blue Cross Blue Shield of Kansas·KS · Endocrinology, Hematology, Oncology +3 more·Pharmacy
Effective date
Mar 1, 2023
We identified it
Jun 19, 2026
Summary
BCBSKS has updated 9 pharmacy medical policies effective March 1, 2023, including Camzyos, Long Acting Insulin, HEMLIBRA, Human Fibrinogen Concentrate, IL-4 and IL-5 Inhibitors, Lysosomal Storage Disorders, Relyvrio, and Spevigo. These policies are managed through Prime Therapeutics and may affect prior authorization requirements for these specialty medications.
Action Required
By March 1, 2023: Billing and clinical teams must review updated pharmacy medical policies for Camzyos, Long Acting Insulin, HEMLIBRA, Human Fibrinogen Concentrate, IL-4 Inhibitors, IL-5 Inhibitors, Lysosomal Storage Disorders, Relyvrio, and Spevigo at https://www.bcbsks.com/providers/precertification-prior-authorization. Update prior authorization workflows for these medications and verify current requirements before prescribing or billing.